U.S. Food and Drug Administration (USFDA) has issued Establishment Inspection Report (EIR) to Natco Pharma’s Active Pharmaceutical Ingredient (API) division located in Mekaguda, Hyderabad, India on July 24, 2025.
USFDA had conducted an inspection at said facility from June 9, 2025 to June 13, 2025.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
